Monopar's MNPR-101-Zr Clinical Trial Update

Monopar Therapeutics, a biopharmaceutical firm listed on Nasdaq as MNPR, is advancing its Phase 1 dosimetry clinical trial for MNPR-101-Zr, a potential treatment for advanced cancers. The company has appointed Professor Rodney Hicks, a distinguished expert in radiopharmaceuticals, to spearhead the study. Hicks, who has been instrumental in the approval of radiopharmaceutical agents for various cancers and was honored with the Saul Hertz Award in 2023, will conduct the trial at the Melbourne Theranostic Innovation Centre (MTIC). The trial will employ the Siemens Biograph Vision Quadra, an advanced PET/CT scanner, to assess the drug's targeting capabilities in cancer patients.

Monopar's CEO, Dr. Chandler Robinson, expressed enthusiasm about Hicks' involvement, highlighting his pioneering work in radiopharmaceuticals and his role in establishing the first PET/CT scanner in Australia. Hicks, who is also the founder of MTIC, has a prolific research background with over 650 publications and is committed to facilitating patient access to novel radiopharmaceuticals.

The MNPR-101-Zr drug is under development to address severe medical needs, particularly for pancreatic and triple-negative breast cancers. The clinical trial's Phase 1 dosimetry data and related preclinical findings are accessible online. Monopar Therapeutics is dedicated to creating innovative cancer treatments and has a pipeline that includes camsirubicin for soft tissue sarcoma and an early-stage analog, MNPR-202.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!